Effect of Potent P2Y₁₂ Inhibitors on Ventricular Arrhythmias and Cardiac Dysfunction in Coronary Artery Disease: A Systematic Review and Meta-Analysis

Table 1

Characteristics, designs, and follow-up durations of the included studies.

Name	Year	Intervention	Potent inhibitors, n	Clopidogrel, n	Characteristics of Study Population	Primary Endpoint	Follow-up
DISPERSE-2 [11]	2007	Ticagrelor vs Clopidogrel	663	327	Patients were hospitalized for NSTE-ACS within the preceding 48 hours.	Major adverse cardiac event; Major bleeding (fatal/life-threatening)	12 weeks; (primary endpoint)
PLATO [1]	2009	Ticagrelor vs Clopidogrel	9333	9291	Hospitalized patients with ACS.	CV death, MI, or stroke; Major bleeding, study criteria	12 months; (primary endpoint)
PHILO [12]	2015	Ticagrelor vs Clopidogrel	387	380	Patients with non-ST or ST segment elevation ACS	Major adverse cardiac event; Major bleeding	12 months; (primary endpoint)
JUMBO-TIMI26 [13]	2005	Prasugrel vs Clopidogrel	651	254	Patients candidate for elective or urgent PCI with intended coronary stenting.	Major adverse cardiac event; Non-CABG TIMI Major or Minor Bleeding Events	30 days; (primary endpoint)
TRITON-TIMI 38 [2]	2007	Prasugrel vs Clopidogrel	6741	6716	Patients with ACS and scheduled for PCI	CV death, nonfatal MI, or nonfatal stroke; TIMI non-CABG major bleeding	14.5 months; (median)
Ge et al. [14]	2010	Prasugrel vs Clopidogrel	463	299	East or southeast Asian patients with ACS and scheduled for PCI.	ADP-Induced PRU at 4 hours and 30 days	30 days; (primary endpoint)
TRILOGY ACS [15]	2012	Prasugrel vs Clopidogrel	4623	4617	Patients with ACS who were medically managed.	CV death, nonfatal MI, or nonfatal stroke; TIMI non-CABG major bleeding	17.1 months; (median)
TRIGGER PCI [16]	2012	Prasugrel vs Clopidogrel	210	210	Coronary artery disease patients underwent PCI with at least one drug-eluting stent implantation.	Composite endpoint of CV death or MI	6 months; (primary endpoint)
ETAMI [17]	2015	Prasugrel vs Clopidogrel	31	31	Patients with acute STEMI ≤ 12 hours and scheduled for PCI	Platelet reactivity index (PRI) 2 hours after the initiation of the therapy	30 days; (clinical events)

DISPERSE-2: dose confirmation study assessing anti-platelet effects of AZD6140 vs. clopidogrel in non-ST-segment elevation myocardial infarction-2, PLATO: platelet inhibition and patient outcomes, PHILO: ticagrelor vs. clopidogrel in Japanese, Korean, and Taiwanese patients with acute coronary syndrome, JUMBO-TIMI26: joint utilization of medications to block platelets optimally-thrombolysis in myocardial infarction 26, TRITON-TIMI 38: trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction, TRILOGY ACS: the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes, TRIGGER PCI: testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel, ETAMI: early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction, PCI: percutaneous coronary intervention, NSTE-ACS: non-ST-segment elevation acute coronary syndrome, ACS: acute coronary syndrome, CABG: coronary artery bypass grafting, CV: cardiovascular, TIMI: thrombolysis in myocardial infarction, MI: myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, STEMI: ST-segment elevation myocardial infarction, GUSTO: Global use of strategies to open occluded coronary arteries, ADP: adenosine diphosphate, PRU: reaction units.